Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study
Cancer Medicine · 2023
DOI: 10.1002/cam4.6494 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Takashi Yokokawa und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Nausea, Vomiting, Menopause. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japanese Society of Pharmaceutical Oncology.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Female sex and younger age are reported risk factors for chemotherapy‐induced nausea and vomiting (CINV) in highly emetogenic chemotherapy, but the underlying mechanism has not been elucidated. The purpose of this study was to clarify the impact of menopause on CINV.
Methods
This retrospective observational study analyzed data from consecutive patients who received their first cycle of perioperative anthracycline‐based chemotherapy for breast cancer between January 2018 and June 2020. The endpoints were association between CINV (vomiting, ≥Grade 2 nausea, complete response [CR] failure) and menopause as well as the association between CINV and follicle‐stimulating hormone [FSH]/estradiol [E2].
Results
Data for 639 patients were analyzed. Among these patients, 109 (17.1%) received olanzapine (four antiemetic combinations) and 530 (82.9%) did not (three antiemetic combinations). Premenopausal state (amenorrhea lasting ≥12 months) was significantly associated with ≥Grade 2 nausea and CR failure in univariate analysis but not in multivariate analysis. The premenopausal FSH/E2 group (defined by serum levels; FSH
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
- Department of Clinical Pharmacology and Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
- Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan.
ORCID-Profile: Takashi Yokokawa, Daiki Tsuji, Kazuo Kobayashi, Kazuyoshi Kawakami, Hitoshi Kawazoe, Takeshi Aoyama, Koki Hashimoto, Masahiro Hatori, Takuya Tomomatsu
Förderung
- Japanese Society of Pharmaceutical Oncology
Zitieren
APA
Yokokawa, T., Suzuki, K., Tsuji, D., Hosonaga, M., Kobayashi, K., Kawakami, K., Kawazoe, H., Nakamura, T., Suzuki, W., Sugisaki, T., Aoyama, T., Hashimoto, K., Hatori, M., Tomomatsu, T., Inoue, A., Azuma, K., Asano, M., Takano, T., Ohno, S., & Yamaguchi, M. (2023). Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study. Cancer Medicine. https://doi.org/10.1002/cam4.6494
Vancouver
Yokokawa T, Suzuki K, Tsuji D, Hosonaga M, Kobayashi K, Kawakami K, et al. Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study. Cancer Medicine. 2023. doi:10.1002/cam4.6494
BibTeX
@article{Yokokawa2023,
author = {Yokokawa, Takashi and Suzuki, Kenichi and Tsuji, Daiki and Hosonaga, Mari and Kobayashi, Kazuo and Kawakami, Kazuyoshi and Kawazoe, Hitoshi and Nakamura, Tomonori and Suzuki, Wataru and Sugisaki, Takahito and Aoyama, Takeshi and Hashimoto, Koki and Hatori, Masahiro and Tomomatsu, Takuya and Inoue, Ayaka and Azuma, Keiichi and Asano, Maimi and Takano, Toshimi and Ohno, Shinji and Yamaguchi, Masakazu},
title = {Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6494}
}
EUVIMED